Medicine Overview
Adult Dose
| Clinical Information | Administration Information |
|---|---|
|
Age: Adult |
Dose: Tablet – 1 tablet Frequency: twice daily Note: Administered by mouth (oral). |
Child Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: HIV-1 infection Age: Pediatric |
Dose: Tablet – 1 tablet (150 mg lamivudine, 200 mg nevirapine, and 300 mg zidovudine) Frequency: twice daily Note: by mouth (oral) |
Renal Dose
| Clinical Information | Administration Information |
|---|---|
|
Condition: Renal impairment: Creatinine Clearance (milliliters per minute) less than 50 |
Dose: Dose: Note: Avoid |
Administration
- Take as directed
- Regular timing
Side Effect
- Headache
- malaise and fatigue
- fever or chills
- nausea
- diarrhoea
- anorexia
- abdominal pain
- neuropathy
- insomnia and other sleep disorders
- dizziness
- depressive disorders
- nasal signs and symptoms
- skin rashes
- musculoskeletal pain
- myalgia
- arthralgia
- anaemia
- neutropenia and leucopenia (particularly at high doses of zidovudine
- 1200-1500 mg/day)
- usually seen 4-5 wk after therapy commencing
- respiratory symptoms eg rapid and/or deep breathing
- if symptomatic hyperlactatemia
- metabolic/lactic acidosis
- progressive hepatomegaly
- or rapidly elevating aminotransferase levels occur
- withdraw treatment
- mitochondrial damage leading to hyperlactatemia and hyperlipasemia
- lipodystrophy
- immune reactivation syndrome
- osteonecrosis
- Lactic acidosis associated with liver failure and pancreatitis (normally after several mth of treatment)
- haematological toxicity (eg neutropenia and severe anaemia)
Drug Interaction
Drug Interaction
| Drug Name | Risk Factors |
|---|---|
|
Acyclovir, Valacyclovir
|
May increase CNS depression (for Zidovudine)
|
|
Ganciclovir, Valganciclovir, Dapsone, Doxorubicin, Vincristine, Vinblastine
|
Increased risk of haematologic toxicity (for Zidovudine)
|
Disease Interaction
Disease Interaction
| Disease Name | Risk Factors |
|---|---|
|
Neutrophil count <0.75 x 109/L
|
Risk of severe infections
|
|
Hemoglobin levels <5 g/dL
|
Risk of severe anemia
|
Pregnancy
Pregnancy
Lactation
Special Use
Precaution
Overdose
Pharmacology
Storage
Details coming soon
Data Sources
Clinical & regulatory information on this page is compiled from the following government sources:
DISCLAIMER: This drug information content is provided for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always consult their physician with any questions regarding a medical condition and to obtain medical advice and treatment.